<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000513009"><TermName>N-benzoyl-staurosporine</TermName><TermPronunciation>(...BEN-zoyl-STAW-roh-SPOR-een)</TermPronunciation><TermDefinition><DefinitionText>A substance that is being studied in the treatment of leukemia. It belongs to the family of drugs called protein kinase inhibitors. Also called midostaurin and PKC412.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718419" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;N-benzoyl-staurosporine&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718418" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;N-benzoilo-estaurosporina&quot;" language="es" id="_4"/><SpanishTermName>N-benzoilo-estaurosporina</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de la leucemia. Es un tipo de inhibidor de la proteína cinasa. También se llama midostaurin y PKC412.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-10-14</DateFirstPublished><DateLastModified>2007-03-15</DateLastModified></GlossaryTerm>
